OncoMatch/Clinical Trials/NCT06463028
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
Is NCT06463028 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Sapanisertib and Serabelisib for endometrial cancer.
Treatment: Sapanisertib · Serabelisib · Paclitaxel — This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Must have received: checkpoint inhibitor
Lab requirements
Cardiac function
Significant cardiovascular impairment; Prolongation of QTc interval to >480 ms
Significant cardiovascular impairment. Prolongation of QTc interval to >480 ms.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC San Diego Moores Cancer Center · La Jolla, California
- University of California, San Francisco (UCSF) · San Francisco, California
- Mount Sinai Comprehensive Cancer Center · Miami Beach, Florida
- Florida Cancer Specialists, North · St. Petersburg, Florida
- Florida Cancer Specialists, East · West Palm Beach, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify